Rezim Tablet 100 mg contains Resmetirom, a novel and targeted thyroid hormone receptor‑β (THR‑β) agonist developed to manage non‑alcoholic steatohepatitis (NASH) — a progressive form of non‑alcoholic fatty liver disease (NAFLD). NASH is marked by excessive liver fat, inflammation, and fibrosis (scarring), and can lead to serious complications such as cirrhosis and liver failure if left untreated. Rezim offers a promising therapeutic option by addressing the metabolic root causes of the disease rather than just alleviating symptoms.

This higher‑strength formulation is designed for patients who require a greater pharmacologic effect to achieve meaningful clinical benefits, such as significant reduction of liver fat and improvement in liver histology.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each tablet contains:

• Resmetirom 100 mg

Indications

Rezim Tablet 100 mg is indicated for:

• Management of non‑alcoholic steatohepatitis (NASH) in adults

• Reduction of hepatic fat content in patients with NAFLD/NASH

• Improvement of metabolic parameters associated with liver disease, including dyslipidemia

• Supportive treatment for adults with NASH and evidence of liver fibrosis

• Adjunctive therapy in metabolic liver disorders under physician guidance

Mechanism of Action

Resmetirom selectively activates thyroid hormone receptor‑β, which is predominantly expressed in the liver. This targeted action results in several beneficial effects:

• Enhanced hepatic fatty acid oxidation: Resmetirom stimulates pathways that increase the breakdown and clearance of liver fat.

• Improved lipid metabolism: It helps lower levels of low‑density lipoprotein (LDL) cholesterol and triglycerides, addressing key metabolic risk factors often seen in NASH patients.

• Anti‑inflammatory effects: By reducing liver inflammation, Resmetirom helps slow the progression of disease.

• Antifibrotic benefits: The medication may help stabilize or reduce liver fibrosis, a major factor in long‑term clinical outcomes.

This multifaceted mechanism offers a more comprehensive approach to treating NAFLD/NASH than traditional therapies.

Dosage and Administration

• The recommended dosage is 100 mg once daily, taken orally with or without food.

• Swallow the tablet whole with water; do not crush, chew, or break unless advised by a healthcare professional.

• The duration of therapy will be determined by the physician based on disease severity, clinical response, and ongoing monitoring.

• Regular evaluation of liver function tests, lipid parameters, and metabolic markers is advised throughout treatment.

Precautions and Warnings

• Use with caution in patients with pre‑existing thyroid disorders or significant hormonal imbalances.

• Not recommended in patients with severe liver impairment unless specifically supervised by a liver specialist.

• Inform your healthcare provider of all concurrent medications, as certain drugs may interact with resmetirom or require dosage adjustments.

• Pregnant or breastfeeding women should use only if the potential benefits outweigh the risks, and only under medical supervision.

• Continuous monitoring is important to assess therapeutic benefits and identify any potential side effects early.

Possible Side Effects

Rezim Tablet 100 mg is generally well tolerated. Potential side effects may include:

• Mild gastrointestinal discomfort (such as nausea or abdominal pain)

• Headache

• Fatigue or dizziness

• Rare changes in thyroid hormone levels

• Alterations in lipid parameters that may require dose adjustment or clinical monitoring

Serious adverse events are uncommon but should be evaluated by a healthcare provider if they occur.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage Instructions

• Store below 30°C in a cool, dry place.

• Protect from light and moisture.

• Keep out of reach of children.

Conclusion

Rezim Tablet 100 mg (Resmetirom) is a targeted treatment option for adults with non‑alcoholic steatohepatitis (NASH). By enhancing liver fat metabolism, improving lipid profiles, reducing inflammation, and potentially slowing fibrosis, Rezim addresses key drivers of the disease. Under proper medical supervision, it offers a comprehensive approach to managing this chronic liver condition and improving patient outcomes.